• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无症状儿童中产艰难梭菌的检出率:系统评价和荟萃分析。

Prevalence of Detection of Clostridioides difficile Among Asymptomatic Children: A Systematic Review and Meta-analysis.

机构信息

Cumming School of Medicine, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.

Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.

出版信息

JAMA Pediatr. 2021 Oct 1;175(10):e212328. doi: 10.1001/jamapediatrics.2021.2328. Epub 2021 Oct 4.

DOI:10.1001/jamapediatrics.2021.2328
PMID:34338715
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8329794/
Abstract

IMPORTANCE

Detection of Clostridioides difficile has frequently been described in asymptomatic infants and children, but accurate estimates across the age spectrum are unavailable.

OBJECTIVE

To assess the prevalence of C difficile detection among asymptomatic children across the age spectrum.

DATA SOURCES

This systematic review and meta-analysis included a search of the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, CINAHL, Scopus, and Web of Science for articles published from January 1, 1990, to December 31, 2020. Search terms included Clostridium difficile, Peptoclostridium difficile, Clostridioides difficile, CDF OR CDI OR c diff OR c difficile, Clostridium infections OR cd positive diarrhea OR cd positive diarrhea OR Clostridium difficile OR Peptoclostridium difficile OR pseudomembranous colitis OR pseudomembranous enterocolitis, enterocolitis, and pseudomembranous. These were combined with the following terms: bacterial colonization and colonization OR colonized OR colonizing OR epidemiology OR prevalence OR seroprevalence.

STUDY SELECTION

Studies were screened independently by 2 authors. Studies were included if they reported testing for C difficile among asymptomatic children (ie, children without diarrhea) younger than 18 years.

DATA EXTRACTION AND SYNTHESIS

Data were extracted independently and in duplicate by 2 reviewers. Preferred Reporting Items for a Systematic Review and Meta-analysis (PRISMA) guidelines were used. Data were pooled using a random-effects model.

MAIN OUTCOMES AND MEASURES

The primary outcome was prevalence of C difficile detection among asymptomatic children. Secondary outcomes included prevalence of toxigenic vs nontoxigenic strains of C difficile and prevalence of C difficile detection stratified by geographic region, income status, testing method, and year of testing.

RESULTS

A total of 95 studies with 19 186 participants were included. Rates of detection of toxigenic or nontoxigenic C difficile were greatest among infants aged 6 to 12 months (41%; 95% CI, 32%-50%) and decreased to 12% (95% CI, 7%-18%) among children aged 5 to 18 years. The prevalence of toxigenic C difficile colonization was lower, peaking at 14% (95% CI, 8%-21%) among infants aged 6 to 12 months and decreasing to 6% (95% CI, 2%-11%) among children older than 5 years. Although prevalence differed by geographic region (ie, North and South America vs Europe: β, -0.151, P = .001; North and South America vs Western Pacific: β, 0.136, P = .007), there was no difference by testing method (ie, culture vs polymerase chain reaction: β, 0.069, P = .052; culture vs enzyme immunoassay: β, -0.178, P = .051), income class (low-middle income vs high income: β, -0.144, P = .23; upper-middle vs high income: β, -0.020, P = .64), or period (before 1990 vs 2010-2020: β, -0.125, P = .19; 1990-1999 vs 2010-2020: β, -0.037, P = .42; 2000-2009 vs 2010-2020: β, -0.006, P = .86).

CONCLUSIONS AND RELEVANCE

In this systematic review and meta-analysis, C difficile colonization rates among children were greatest at 6 to 12 months of age and decreased thereafter. These estimates may provide context for interpreting C difficile test results among young children.

摘要

重要性

已有研究频繁报道了无症状婴儿和儿童中艰难梭菌的检出情况,但针对各年龄段的准确估计数据尚不可用。

目的

评估各年龄段无症状儿童中艰难梭菌检测的流行率。

数据来源

本系统评价和荟萃分析纳入了从 1990 年 1 月 1 日至 2020 年 12 月 31 日发表的 Cochrane 对照试验注册中心、MEDLINE、Embase、CINAHL、Scopus 和 Web of Science 的文章进行搜索。检索词包括艰难梭菌、艰难梭状芽胞杆菌、艰难梭菌、CDF 或 CDI 或 c 差或 c 困难、艰难梭菌感染或 cd 阳性腹泻或 cd 阳性腹泻或艰难梭菌或艰难梭状芽胞杆菌或伪膜性结肠炎或伪膜性肠炎、肠炎和伪膜性、细菌定植和定植或定植或定植或流行病学或流行率或血清流行率。这些与以下术语结合使用:细菌定植和定植或定植或定植或流行病学或流行率或血清流行率。

研究选择

两名作者独立筛选研究。如果研究报告了对年龄小于 18 岁且无腹泻的无症状儿童(即无症状儿童)进行艰难梭菌检测,则纳入研究。

数据提取和综合

两名评审员独立并重复提取数据。采用首选报告项目(PRISMA)指南。使用随机效应模型对数据进行汇总。

主要结果和措施

主要结局为无症状儿童中艰难梭菌检测的流行率。次要结局包括产毒与非产毒艰难梭菌的流行率以及艰难梭菌检测的流行率,按地理位置、收入状况、检测方法和检测年份进行分层。

结果

共纳入 95 项研究,涉及 19 186 名参与者。6 至 12 个月大婴儿的产毒或非产毒艰难梭菌检出率最高(41%,95%CI,32%-50%),5 至 18 岁儿童的检出率降至 12%(95%CI,7%-18%)。艰难梭菌定植的产毒率较低,6 至 12 个月大婴儿的产毒率最高(14%,95%CI,8%-21%),5 岁以上儿童的产毒率降至 6%(95%CI,2%-11%)。尽管地理位置(北美和南美与欧洲:β,-0.151,P=0.001;北美和南美与西太平洋:β,0.136,P=0.007)存在差异,但检测方法(即培养与聚合酶链反应:β,0.069,P=0.052;培养与酶免疫测定:β,-0.178,P=0.051)、收入类别(中低收入与高收入:β,-0.144,P=0.23;中上收入与高收入:β,-0.020,P=0.64)或时间(1990 年前与 2010-2020 年:β,-0.125,P=0.19;1990-1999 年与 2010-2020 年:β,-0.037,P=0.42;2000-2009 年与 2010-2020 年:β,-0.006,P=0.86)均无差异。

结论和相关性

在本系统评价和荟萃分析中,儿童艰难梭菌定植率在 6 至 12 个月龄时最高,此后逐渐下降。这些估计结果可能为解读幼儿艰难梭菌检测结果提供了依据。

相似文献

1
Prevalence of Detection of Clostridioides difficile Among Asymptomatic Children: A Systematic Review and Meta-analysis.无症状儿童中产艰难梭菌的检出率:系统评价和荟萃分析。
JAMA Pediatr. 2021 Oct 1;175(10):e212328. doi: 10.1001/jamapediatrics.2021.2328. Epub 2021 Oct 4.
2
Prevalence and antimicrobial resistance pattern of Clostridium difficile among hospitalized diarrheal patients: A systematic review and meta-analysis.艰难梭菌在住院腹泻患者中的流行情况及耐药模式:一项系统评价和荟萃分析。
PLoS One. 2022 Jan 13;17(1):e0262597. doi: 10.1371/journal.pone.0262597. eCollection 2022.
3
Prevalence and risk factors for asymptomatic Clostridium difficile carriage.无症状艰难梭菌携带的患病率及危险因素
Clin Infect Dis. 2014 Jul 15;59(2):216-22. doi: 10.1093/cid/ciu258. Epub 2014 Apr 21.
4
Molecular Epidemiology of Clostridioides difficile Infections in Children.儿童艰难梭菌感染的分子流行病学研究。
J Pediatric Infect Dis Soc. 2021 Nov 17;10(Supplement_3):S34-S40. doi: 10.1093/jpids/piab057.
5
One-day prevalence of asymptomatic carriage of toxigenic and non-toxigenic Clostridioides difficile in 10 French hospitals.10 家法国医院产毒和非产毒艰难梭菌无症状携带的日患病率。
J Hosp Infect. 2022 Nov;129:65-74. doi: 10.1016/j.jhin.2022.05.011. Epub 2022 May 28.
6
Prevalence of Clostridium difficile infection and colonization in a tertiary hospital and elderly community of North-Eastern Peninsular Malaysia.马来西亚半岛东北部一家三级医院及老年社区中艰难梭菌感染与定植的患病率
Epidemiol Infect. 2017 Oct;145(14):3012-3019. doi: 10.1017/S0950268817002011. Epub 2017 Sep 11.
7
Whole-Genome Sequencing Reveals the High Nosocomial Transmission and Antimicrobial Resistance of Clostridioides difficile in a Single Center in China, a Four-Year Retrospective Study.全基因组测序揭示中国单中心艰难梭菌的高医院内传播和耐药性:一项四年回顾性研究。
Microbiol Spectr. 2022 Feb 23;10(1):e0132221. doi: 10.1128/spectrum.01322-21. Epub 2022 Jan 12.
8
Detection of Clostridioides difficile toxin B gene: benefits of identifying gastrointestinal pathogens by mPCR assay in the diagnosis of diarrhea in pediatric patients.检测艰难梭菌毒素 B 基因:mPCR 检测法在儿科患者腹泻诊断中对胃肠道病原体鉴定的益处。
BMC Infect Dis. 2022 Feb 5;22(1):126. doi: 10.1186/s12879-022-07104-z.
9
Risk factors for colonization among hospitalized adults: A meta-analysis and systematic review.住院成人定植风险因素:荟萃分析和系统评价。
Infect Control Hosp Epidemiol. 2021 May;42(5):565-572. doi: 10.1017/ice.2020.1236. Epub 2020 Oct 29.
10
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.益生菌用于预防成人和儿童艰难梭菌相关性腹泻
Cochrane Database Syst Rev. 2013 May 31(5):CD006095. doi: 10.1002/14651858.CD006095.pub3.

引用本文的文献

1
Management of infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10).血液系统恶性肿瘤患者及细胞治疗后感染的管理:第十届欧洲白血病感染会议(ECIL-10)指南
EClinicalMedicine. 2025 Aug 7;87:103371. doi: 10.1016/j.eclinm.2025.103371. eCollection 2025 Sep.
2
Current state of microbiota clinical applications in neonatal and pediatric bacterial infections.新生儿及儿童细菌感染中微生物群临床应用的现状
Gut Microbes. 2025 Dec;17(1):2529400. doi: 10.1080/19490976.2025.2529400. Epub 2025 Jul 6.
3
Clostridioides difficile concentration-dependant alterations in gut microbiota of asymptomatic infants.艰难梭菌对无症状婴儿肠道微生物群的浓度依赖性改变
Gut Pathog. 2025 Apr 4;17(1):17. doi: 10.1186/s13099-025-00687-3.
4
Opportunities for collaboration: the synergy between antimicrobial and diagnostic stewardship in pediatrics.合作机会:儿科抗菌药物管理与诊断管理之间的协同作用
Antimicrob Steward Healthc Epidemiol. 2025 Feb 7;5(1):e32. doi: 10.1017/ash.2024.464. eCollection 2025.
5
Heterogeneity of Clostridioides difficile asymptomatic colonization prevalence: a systematic review and meta-analysis.艰难梭菌无症状定植患病率的异质性:一项系统评价和荟萃分析。
Gut Pathog. 2025 Jan 27;17(1):6. doi: 10.1186/s13099-024-00674-0.
6
Infections in Children: What Is the Optimal Laboratory Diagnostic Method?儿童感染:最佳实验室诊断方法是什么?
Microorganisms. 2024 Aug 28;12(9):1785. doi: 10.3390/microorganisms12091785.
7
infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.感染:历史、流行病学、风险因素、预防、临床表现、治疗和未来选择。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29.
8
Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?益生菌(尤其是布拉氏酵母菌 CNCM I-745 和鼠李糖乳杆菌 GG)的循证应用能否减轻抗生素相关性生态失调的临床影响?
Adv Ther. 2024 Mar;41(3):901-914. doi: 10.1007/s12325-024-02783-3. Epub 2024 Jan 30.
9
Factors Associated With Actionable Gastrointestinal Panel Results in Hospitalized Children.与住院儿童有临床意义的胃肠道Panel 检测结果相关的因素。
Hosp Pediatr. 2023 Dec 1;13(12):1115-1123. doi: 10.1542/hpeds.2023-007273.
10
Dysregulated Immunity to Clostridioides difficile in IBD Patients Without a History of Recognized Infection.炎症性肠病患者在无明确感染史的情况下,对艰难梭菌的免疫失调。
Inflamm Bowel Dis. 2024 May 2;30(5):820-828. doi: 10.1093/ibd/izad238.